Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Cholesterol. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OSBP | P22059 | 5/20 | 0.91 |
| ▸ | RORC | P51449 | 3/20 | 0.91 |
| ▸ | OSBP2 | Q969R2 | 2/20 | 0.91 |
| ▸ | USP2 | O75604 | 1/20 | 0.91 |
| ▸ | LMNA | P02545 | 1/20 | 0.91 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.91 |
| ▸ | CYP46A1 | Q9Y6A2 | 1/20 | 0.91 |
| ▸ | NR1H3 | Q13133 | 8/20 | 0.78 |
| ▸ | EPHA2 | P29317 | 1/20 | 0.78 |
| ▸ | GRIN1 | Q05586 | 4/20 | 0.78 |
| ▸ | GRIN2A | Q12879 | 4/20 | 0.78 |
| ▸ | NPC1L1 | Q9UHC9 | 2/20 | 0.74 |
| ▸ | CRYAB | P02511 | 1/20 | 0.74 |
| ▸ | HMGCR | P04035 | 1/20 | 0.74 |
| ▸ | ITGB3 | P05106 | 1/20 | 0.74 |
| ▸ | ITGAV | P06756 | 1/20 | 0.74 |
| ▸ | SREBF2 | Q12772 | 1/20 | 0.74 |
| ▸ | GRIN2B | Q13224 | 3/20 | 0.73 |
| ▸ | POLA1 | P09884 | 1/20 | 0.72 |
| ▸ | DHCR24 | Q15392 | 2/20 | 0.71 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Cholesterol SCHEMBL31090041 | 1.00 | OSBP (0.91) | OSBPRORCOSBP2USP2LMNA | |
| Cholesterol SCHEMBL1369602 | 0.97 | OSBP (0.93) | OSBPRORCOSBP2USP2LMNA | |
| Cholesterol SCHEMBL29502101 | 0.97 | OSBP (0.93) | OSBPRORCOSBP2USP2LMNA | |
| Cholesterol SCHEMBL27668883 | 0.97 | OSBP (0.93) | OSBPRORCOSBP2USP2LMNA | |
| Cholesterol SCHEMBL27608874 | 0.96 | OSBP (0.91) | OSBPRORCOSBP2USP2LMNA | |
| Cholesterol SCHEMBL25657 | 0.96 | OSBP (0.91) | OSBPRORCOSBP2USP2LMNA | |
| Cholesterol SCHEMBL27420666 | 0.96 | OSBP (0.91) | OSBPRORCOSBP2USP2LMNA | |
| Cholesterol SCHEMBL29491181 | 0.96 | OSBP (0.91) | OSBPRORCOSBP2USP2LMNA | |
| Cholesterol SCHEMBL2460866 | 0.96 | OSBP (0.98) | OSBPRORCOSBP2USP2LMNA | |
| Cholesterol SCHEMBL27893800 | 0.96 | OSBP (0.98) | OSBPRORCOSBP2USP2LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 31 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12545636-B2 | Acyclic lipids and methods of use thereof | RENAGADE THERAPEUTICS MANAGEMENT INC. (US) | 2026-02-10 | — | — | US | disclosed |
| EP-4655402-A1 | NUCLEIC ACID VACCINES FOR VARICELLA-ZOSTER VIRUS (VZV) | Providence Therapeutics Holdings Inc. (CA) | 2025-12-03 | — | — | EP | disclosed |
| EP-4634388-A1 | COMPOSITIONS AND METHODS FOR INFECTIOUS DISEASES | Providence Therapeutics Holdings Inc. (CA) | 2025-10-22 | — | — | EP | disclosed |
| US-20250319190-A1 | APOE LIPOPROTEIN SYSTEMS | KISBEE THERAPEUTICS INC (US) | 2025-10-16 | — | — | US | disclosed |
| US-20250313525-A1 | CONSTRAINED LIPIDS AND METHODS OF USE THEREOF | RENAGADE THERAPEUTICS MAN INC (US) | 2025-10-09 | — | — | US | disclosed |
| US-20250154102-A1 | CYCLIC LIPIDS AND METHODS OF USE THEREOF | RENAGADE THERAPEUTICS MAN INC (US) | 2025-05-15 | — | — | US | disclosed |
| WO-2025061153-A1 | RNA-LIPID PARTICLES COMPRISING POLYSARCOSINE-LIPID CONJUGATE | Everest Medicines (China) Co., Ltd. (CN) | 2025-03-27 | — | — | WO | disclosed |
| EP-4522646-A2 | APOE LIPOPROTEIN SYSTEMS | Kisbee Therapeutics, Inc. (US) | 2025-03-19 | — | — | EP | disclosed |
| US-20250073164-A1 | IONIZABLE DISULFIDE LIPIDS AND LIPID NANOPARTICLES DERIVED THEREFROM | PROVIDENCE THERAPEUTICS HOLDINGS INC. (CA) | 2025-03-06 | — | — | US | disclosed |
| US-12215068-B2 | Constrained lipids and methods of use thereof | RENAGADE THERAPEUTICS MANAGEMENT INC. (US) | 2025-02-04 | — | — | US | disclosed |
| WO-2023137550-A1 | COMPOSITIONS AND METHODS FOR THE PREVENTION AND/OR TREATMENT OF COVID-19 | PROVIDENCE THERAPEUTICS HOLDINGS INC. (CA) | 2023-07-27 | — | — | WO | disclosed |
| US-20230202977-A1 | CYCLIC LIPIDS AND METHODS OF USE THEREOF | RENAGADE THERAPEUTICS MANAGEMENT INC. | 2023-06-29 | — | — | US | disclosed |
| US-20230202966-A1 | ACYCLIC LIPIDS AND METHODS OF USE THEREOF | RENAGADE THERAPEUTICS MANAGEMENT INC. | 2023-06-29 | — | — | US | disclosed |
| WO-2023122752-A1 | CONSTRAINED LIPIDS AND METHODS OF USE THEREOF | RENAGADE THERAPEUTICS MANAGEMENT INC. (US) | 2023-06-29 | — | — | WO | disclosed |
| WO-2023115221-A1 | IONIZABLE DILSULFIDE LIPIDS AND LIPID NANOPARTICLES DERIVED THEREFROM | PROVIDENCE THERAPEUTICS HOLDINGS INC. (CA) | 2023-06-29 | — | — | WO | disclosed |
| WO-2023050003-A1 | COMPOSITIONS AND METHODS FOR THE PREVENTION AND/OR TREATMENT OF COVID-19 | PROVIDENCE THERAPEUTICS HOLDINGS INC. (CA) | 2023-04-06 | — | — | WO | disclosed |
| WO-2023044333-A1 | CYCLIC LIPIDS AND METHODS OF USE THEREOF | RENAGADE THERAPEUTICS MANAGEMENT INC. (US) | 2023-03-23 | — | — | WO | disclosed |
| WO-2023044343-A1 | ACYCLIC LIPIDS AND METHODS OF USE THEREOF | RENAGADE THERAPEUTICS MANAGEMENT INC. (US) | 2023-03-23 | — | — | WO | disclosed |
| WO-2023023055-A1 | COMPOSITIONS AND METHODS FOR OPTIMIZING TROPISM OF DELIVERY SYSTEMS FOR RNA | RENAGADE THERAPEUTICS MANAGEMENT INC. (US) | 2023-02-23 | — | — | WO | disclosed |
| US-11541010-B2 | Amphoteric liposomes comprising imino lipids | BIONTECH DELIVERY TECHNOLOGIES GMBH (DE) | 2023-01-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11541010-B2 | Amphoteric liposomes comprising imino lipids | SGMS1, SGMS2, PHOSPHO1 | OSBP 369/4885RORC 3869/4885OSBP2 312/4885 |
| US-20250313525-A1 | CONSTRAINED LIPIDS AND METHODS OF USE THEREOF | SGMS1, SGMS2, LNPEP | OSBP 770/4885RORC 1880/4885OSBP2 601/4885 |
| US-20250319190-A1 | APOE LIPOPROTEIN SYSTEMS | APOB, APOL1, LDLR | OSBP 140/4885RORC 2949/4885OSBP2 82/4885 |
| US-20250073164-A1 | IONIZABLE DISULFIDE LIPIDS AND LIPID NANOPARTICLES DERIVED THEREFROM | SGMS1, SGMS2, ABCB4 | OSBP 899/4885RORC 1845/4885OSBP2 518/4885 |
| US-12545636-B2 | Acyclic lipids and methods of use thereof | PLTP, LNPEP, PCTP | OSBP 1732/4885RORC 2926/4885OSBP2 2365/4885 |
| US-12215068-B2 | Constrained lipids and methods of use thereof | SGMS1, SGMS2, LNPEP | OSBP 770/4885RORC 1880/4885OSBP2 601/4885 |
| US-20250154102-A1 | CYCLIC LIPIDS AND METHODS OF USE THEREOF | SGMS1, SGMS2, LNPEP | OSBP 471/4885RORC 2514/4885OSBP2 341/4885 |
| US-20230202977-A1 | CYCLIC LIPIDS AND METHODS OF USE THEREOF | SGMS1, SGMS2, LNPEP | OSBP 471/4885RORC 2514/4885OSBP2 341/4885 |
| US-20230202966-A1 | ACYCLIC LIPIDS AND METHODS OF USE THEREOF | SGMS1, SGMS2, ABHD16A | OSBP 749/4885RORC 3290/4885OSBP2 561/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.